The Carcinogenic Potency Project

Hydrazine sulfate (CAS 10034-93-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
liv lun lun liv lun liv lun 40.8m 7.59m,v

Hamsters: Cancer Test Summary
Hamster Target Sites TD50
(mg/kg/day)
Male Female
liv no positive 118m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. lun = lung. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Hydrazine sulfate: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code



HYDRAZINE SULFATE   10034-93-2
3186 H f syg wat 25m25 1108                          0    16.4mg                                     Toth;canr,32,804-807;1972/1967a
 cec tum e      115.mg   P<.004  -  39.6mg 813.mg   0/79    4/40
 thy ade e      124.mg   P<.004  -  42.8mg 895.mg   0/84    4/43
 liv tum e      no dre   P=1.       156.mg n.s.s.   0/84    0/43
 lun tum e      no dre   P=1.       156.mg n.s.s.   0/84    0/43
3187 H m syg wat 28m28 1108                          0    14.4mg
 cec tum e      136.mg   P<.02   -  41.0mg 241.gm   0/64    3/33
 liv hem e      no dre   P=1.    -  23.3mg n.s.s.   1/22    0/6
 lun tum e      no dre   P=1.       194.mg n.s.s.   0/86    0/50
3188 H m syg wat 24m24 1821                          0    20.4mg  40.8mg  61.2mg                           Bosan;carc,8,439-444;1987
 liv hpc er     181.mg * P<.0005 +  95.1mg 431.mg   0/31    0/31    4/31    9/31
 liv mhs er     2.58gm * P<.3       420.mg n.s.s.   0/31    0/31    0/31    1/31
 liv hpa er     2.59gm * P<.5       421.mg n.s.s.   0/31    0/31    1/31    0/31
 liv rts er     2.59gm * P<.5       421.mg n.s.s.   0/31    0/31    1/31    0/31
3189 H m syg wat 91w91 2324                          0    20.4mg  40.8mg  61.2mg        FitzGerald;carc,17,2703-2709;1996/pers.comm.
 liv hpa Cer    87.5mg * P<.002     47.0mg 336.mg   0/8     1/17    3/24   10/23
 liv mix Cer    87.5mg * P<.002  +  47.0mg 336.mg   0/8     1/17    3/24   10/23
 liv hpc Cer    464.mg * P<.2       140.mg n.s.s.   0/8     0/17    1/24    2/23
3190 M f akr wat 69w69 158                           0    24.0mg                                    Toth;jnci,42,469-475;1969a/1966a
 liv tum e      no dre   P=1.    -  87.1mg n.s.s.   0/30    0/40
 lun tum e      no dre   P=1.    -  87.1mg n.s.s.   0/30    0/40
3191 M m akr wat 69w69 158                           0    20.0mg
 lun ade e      no dre   P=1.    -  22.9mg n.s.s.   1/11    1/20
 liv hem e      no dre   P=1.    -  52.6mg n.s.s.   1/16    0/29
3192 M f c3h wat 92w92 158                           0    24.0mg
 lun ade e      109.mg   P<.05   +  37.7mg n.s.s.   0/22    4/36
3193 M f cbc gav 36w74 1074                          0    21.8mg                                    Biancifiori;bjca,18,543-550;1964
 lun mix e      3.35mg   P<.0005 +  1.58mg 7.60mg   4/47   19/21
 liv hpt e      6.27mg   P<.0005 +  3.19mg 14.5mg   2/47   15/21
3194 M m cbc gav 36w84 1074                          0    16.0mg
 lun mix e      5.10mg   P<.0005 +  2.62mg 11.3mg   1/37   16/21
 liv hpt e      8.43mg   P<.0005 +  4.01mg 26.7mg   4/37   13/21
3195 M f ic3 gav 73w73 156                           0    37.7mg                                          Bhide;ijcn,18,530-535;1976
 lun adc        10.3mg   P<.0005 +  5.58mg 21.6mg   0/12   17/24
 liv tum        no dre   P=1.    -  91.9mg n.s.s.   0/12    0/24
3196 M m ic3 gav 73w73 156                           0    31.4mg
 lun adc        79.5mg   P<.2    +  19.5mg n.s.s.   0/12    2/16
 liv tum        no dre   P=1.    -  51.1mg n.s.s.   0/12    0/16
3197 M f swa wat 95w95 158                           0    24.0mg                                    Toth;jnci,42,469-475;1969a/1966a
 lun mix e      23.8mg   P<.0005 +  13.1mg 57.1mg  14/109  24/47
 lun ade e      26.7mg   P<.0005    14.5mg 66.4mg  12/109  22/47
 lun adc e      146.mg   P<.03      49.0mg n.s.s.   2/109   5/47
 liv hem e      no dre   P=1.    -  97.1mg n.s.s.   3/78    1/36
3198 M m swa wat 94w94 158                           0    20.0mg
 lun mix e      18.7mg   P<.0005 +  10.8mg 39.8mg  10/110  25/50
 lun ade e      23.1mg   P<.0005    12.7mg 55.2mg  10/110  22/50
 lun adc e      74.2mg   P<.0005    32.0mg 237.mg   0/110   7/50
 liv mix e      78.4mg   P<.2       18.7mg n.s.s.   2/40    3/17
3199 M b swi gav 54w54 1525                          0    27.6mg                                             Maru;clet,17,75-80;1982
 lun tum r      3.92mg   P<.0005 +  2.23mg 7.57mg   1/47   22/30
 liv tum r      no dre   P=1.       28.4mg n.s.s.   7/47    2/30
3200 M b swi gav 95w95 1552                          0    27.6mg                                         Menon;zkko,105,258-261;1983
 lun adc r      9.81mg   P<.0005 +  6.55mg 15.7mg   1/20   51/63
3201 R f cbs gav 68w94 157                           0    24.7mg                                         Severi;jnci,41,331-349;1968
 lun mix        42.4mg   P<.004  +  16.0mg 274.mg   0/22    5/18
 liv mix e      no dre   P=1.       54.0mg n.s.s.   0/22    0/13
3202 R m cbs gav 68w94 157                           0    25.9mg
 liv mix eh     39.4mg   P<.002  +  13.5mg 231.mg   0/28    4/13
 lun mix        60.1mg   P<.009  +  18.1mg 1.95gm   0/28    3/14
Mutagenicity in Salmonella: positive
SMILES Code for Hydrazine sulfate: OS(=O)(=O)O.NN
InChI Code for Hydrazine sulfate: InChI=1/H4N2.H2O4S/c1-2;1-5(2,3)4/h1-2H2;(H2,1,2,3,4)
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Hydrazine sulfate: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact slone.cpdb@gmail.com.
Last updated: October 3, 2007